Buy Survodutide Peptide | BI 456906 | ≥98% Purity | CoA Included | SourceTides

Buy Survodutide Peptide from SourceTides — the potent 29-amino-acid dual GLP-1R/GCGR agonist (CAS 2805997-46-8; synonym BI 456906) supplied at ≥98% HPLC-verified purity with a full Certificate of Analysis. Survodutide is a C18 fatty-acid-acylated, once-weekly-dosed research compound co-developed by Boehringer Ingelheim and Zealand Pharma, currently in Phase III clinical trials for obesity and MASH. Every SourceTides vial is lyophilised under ISO-grade conditions, independently endotoxin-tested (LAL <1 EU/mg), and dispatched on a validated cold-chain. For in-vitro laboratory and preclinical research use only — not for human consumption.

Survodutide Technical Specifications

What Is Survodutide (BI 456906)?

Survodutide (development code BI 456906; INN: survodutide) is a synthetic, acylated 29-amino-acid peptide that functions as a potent unimolecular dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). It was co-invented by Boehringer Ingelheim and Zealand Pharma and has emerged as one of the most clinically advanced dual receptor agonists in the rapidly growing incretin-based obesity and metabolic disease research landscape.

Unlike most dual GLP-1/glucagon agonists that are derived from oxyntomodulin (the endogenous gut peptide with weak dual receptor activity), Survodutide is specifically derived from the native glucagon sequence — a structural distinction that confers unique pharmacological properties. The molecule incorporates a non-coded amino acid, 1-aminocyclobutane-1-carboxylic acid (Ac4c), at position 2, which blocks the primary DPP-4 cleavage site and substantially extends metabolic stability. A C18 fatty diacid moiety is conjugated via a hydrophilic Gly-Ser linker at the Lys24 residue, mediating high-affinity binding to circulating albumin and extending the functional half-life to approximately one week — enabling the once-weekly subcutaneous administration used across all clinical trials.

The fundamental research rationale for Survodutide lies in its dual receptor mechanism: GLP-1R agonism suppresses appetite, delays gastric emptying, and stimulates glucose-dependent insulin secretion, while GCGR agonism simultaneously increases hepatic energy expenditure, promotes lipolysis, and reduces liver fat accumulation. This complementary dual-axis mechanism theoretically produces superior weight reduction and metabolic improvement compared to selective GLP-1R agonism alone — a hypothesis that Phase 2 clinical data has significantly supported. The compound is now in Phase III trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) for obesity and has received FDA Breakthrough Therapy designation for MASH, placing it among the most clinically validated research peptides available for metabolic biology studies.

Researchers modelling dual receptor agonist signalling, studying metabolic dysfunction-associated steatohepatitis (MASH/NASH), investigating hepatic energy metabolism, or comparing GLP-1 monotherapy versus dual-agonism in preclinical models will find Survodutide from SourceTides an essential and clinically contextualised research tool.

Mechanism of Action: How Survodutide Activates GLP-1R and GCGR

Survodutide’s biological activity is mediated through simultaneous engagement of two distinct G-protein-coupled receptor pathways, each with documented downstream signalling cascades and metabolic consequences. The additive and complementary nature of these two pathways is the mechanistic foundation for Survodutide’s superior efficacy relative to selective GLP-1R agonists in preclinical head-to-head comparisons.

1. GLP-1 Receptor (GLP-1R) Agonism: Appetite Suppression and Glycaemic Control

Survodutide’s GLP-1R agonism (EC₅₀ 0.33 nM in CHO-K1 cells; 0.36 nM in the endogenous mouse GLP-1R in MIN6 insulinoma cells) mediates the anorectic and insulinotropic components of its pharmacological profile. At the GLP-1R, which is expressed in pancreatic beta cells, the brainstem area postrema (AP), and the arcuate nucleus of the hypothalamus (ARH), Survodutide activates Gαs-coupled cAMP signalling to: (1) stimulate glucose-dependent insulin secretion from pancreatic islets; (2) suppress glucagon secretion from alpha cells in a glucose-dependent manner; (3) delay gastric emptying, reducing the rate of postprandial glucose excursions; and (4) activate central appetite-suppressing neural circuits via GLP-1R expressed in brainstem circumventricular organs. A 2025 mechanistic study published in PMC (PMC12925197) specifically characterised that GLP-1R — but not GCGR — is expressed in the area postrema and arcuate nucleus in both human and mouse tissue, confirming that the central anorectic effects of Survodutide are primarily mediated through GLP-1R in these brain regions. In preclinical models, Survodutide produced dose-dependent acute food intake reductions that were absent in GLP-1R knockout mice but preserved in wild-type animals, directly demonstrating GLP-1R dependency for the appetite-suppression component.

2. Glucagon Receptor (GCGR) Agonism: Hepatic Energy Expenditure and Lipolysis

The GCGR component of Survodutide’s dual mechanism (EC₅₀ 0.52 nM in CHO-K1 cells; GLP-1R:GCGR selectivity ratio ≈ 8:1) primarily drives increased energy expenditure and hepatic fat clearance — mechanisms largely absent from selective GLP-1R agonists. GCGR is highly expressed in hepatocytes, and activation stimulates hepatic glycogenolysis, gluconeogenesis, fatty acid oxidation, and thermogenesis. This hepatic GCGR activation increases overall energy expenditure, addressing the metabolic inefficiency (reduced resting metabolic rate) that typically accompanies GLP-1R-driven caloric restriction. A 2025 study (PMC12890723) specifically demonstrated that hepatic GCGR expression is required for the superior weight loss effects of a structurally related Survodutide analog in mice: liver-specific GCGR knockout abolished the compound’s additional weight loss benefit over GLP-1R monotherapy, directly validating hepatic GCGR as the key site of Survodutide’s additive efficacy. The GCGR axis also drives direct effects on hepatic lipid metabolism relevant to MASH: reductions in liver fat content of ≥30% were achieved in 57–67% of Survodutide-treated participants in the Phase 2 MASH trial, compared to only 14% in the placebo group (NEJM, 2024; DOI: 10.1056/NEJMoa2401755).

3. Structural Engineering for Proteolytic Stability and Extended Half-Life

A critical and mechanistically distinctive feature of Survodutide is its engineered resistance to endogenous peptidase degradation, which is what distinguishes it from native glucagon and enables once-weekly dosing. Three structural modifications achieve this: First, the incorporation of Ac4c (1-aminocyclobutane-1-carboxylic acid) at position 2 — the canonical DPP-4 cleavage site for glucagon-like peptides — blocks DPP-4 peptidase activity, preventing the rapid N-terminal truncation that inactivates native GLP-1 (t½ ~1–2 min) and glucagon. Second, C-terminal amidation (–NH₂) protects against carboxypeptidase-mediated degradation. Third, and most consequentially for half-life extension, a C18 fatty diacid is conjugated via a hydrophilic Gly-Ser-Gly-Ser-Gly-Gly-γGlu linker at Lys24. This acylation enables reversible, high-affinity non-covalent binding to circulating human serum albumin, which with its large hydrodynamic radius and slow renal clearance (t½ ~19 days) effectively acts as a pharmacokinetic reservoir, dramatically extending Survodutide’s functional half-life to approximately one week. This is the same albumin-binding engineering strategy used in semaglutide and liraglutide but applied to a dual-agonist glucagon scaffold. Together, these modifications transform an otherwise rapidly degraded peptide into a once-weekly subcutaneous research compound with plasma levels sustained throughout the dosing interval.

4. Central Nervous System Engagement via Circumventricular Organs

Beyond its peripheral actions, Survodutide engages central neural circuits through brain regions lacking a complete blood-brain barrier — the circumventricular organs (CVOs). A mechanistic study published in PMC (PMC12925197) characterised GCGR and GLP-1R expression in human and mouse CVOs, confirming that GLP-1R is expressed in the area postrema and arcuate nucleus while GCGR is barely detectable in these regions at the single-cell level. Survodutide activates neuronal regions associated with appetite regulation via GLP-1R in these CVO tissues, contributing to its potent food intake suppression. Additionally, Survodutide activates cFos expression in broader hypothalamic regions involved in energy balance, indicating engagement of neural circuits beyond those accessible to peripherally restricted GLP-1R agonists.

Survodutide Research Evidence Summary

Survodutide Phase 2 Clinical Evidence: The Strongest Data Domain

Survodutide is exceptional among research peptides in that its preclinical mechanistic data has been directly validated in Phase 2 randomised controlled trials — two of which have published results in top-tier journals and a third in which Phase 3 trials are underway. This depth of clinical contextualisation makes Survodutide uniquely valuable for researchers designing in-vitro or preclinical experiments that need to be anchored to a human-data mechanistic framework.

Phase 2 Obesity Trial (Lancet Diabetes Endocrinol, 2024)

Le Roux et al. published a Phase 2, randomised, double-blind, placebo-controlled dose-finding study (NCT04667377) of Survodutide in people with overweight or obesity without type 2 diabetes, enrolling participants across multiple international sites. Over 46 weeks with four dose levels (0.6, 1.8, 3.6, and 4.8 mg once-weekly subcutaneous), the highest-dose group (4.8 mg) achieved a mean body weight reduction of approximately 14.9–18.7%, with more than 65% of participants achieving ≥15% body weight loss and over 40% achieving ≥20% — benchmarks exceeding those reported in the pivotal semaglutide STEP trials at comparable timepoints. Dose-response was non-flat, with clear superiority of higher doses. Serious adverse events occurred in 4.2% of survodutide-treated participants compared to 6.5% on placebo — an important finding demonstrating that the overall serious event burden was not elevated. The phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials have initiated based on these data, using a more gradual dose-escalation scheme to improve tolerability. This trial is published in Lancet Diabetes & Endocrinology (PMID: 38330987; PubMed link).

Phase 2 MASH Trial (NEJM, 2024) — FDA Breakthrough Therapy

Sanyal et al. published the pivotal Phase 2 trial of Survodutide in MASH and fibrosis in the New England Journal of Medicine (2024; DOI: 10.1056/NEJMoa2401755), representing among the strongest efficacy data sets published for any investigational MASH compound. In this 48-week, randomised, double-blind, placebo-controlled trial (NCT04771273) enrolling 293 participants with biopsy-confirmed MASH and fibrosis stages F1–F3, Survodutide met its primary endpoint: biopsy-proven MASH improvement without worsening of fibrosis, achieved by 47% (2.4 mg group), 62% (4.8 mg group), and 43% (6.0 mg group) of participants, compared to only 14% in the placebo group (p<0.001). Secondary endpoints were also met, including significant improvements in liver fibrosis stage. Liver fat content decreased by ≥30% in 57–67% of treated participants versus 14% on placebo. Boehringer Ingelheim announced these top-line results in March 2024 with an additional headline figure of up to 83% MASH improvement at the highest-responding dose group in a broader analysis. Based on these Phase 2 results, the FDA granted Survodutide Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis (stages F2–F3), and two Phase 3 trials in MASH initiated in 2024.

The SYNCHRONIZE Phase 3 Programme

SYNCHRONIZE-1 and SYNCHRONIZE-2 are the ongoing Phase 3 trials for Survodutide in obesity, with additional Phase 3 MASH trials running in parallel. The SYNCHRONIZE programme incorporates a modified, more gradual dose-escalation scheme specifically designed to address the dose-escalation-phase GI tolerability observed in Phase 2, with flexible up-titration and temporary dose holds permitted. Published in PMC (PMC11664303; SYNCHRONIZE protocol), the Phase 3 design anticipates approximately 10–14% body weight reduction as the survodutide-vs-placebo delta for power calculations — conservative relative to Phase 2 top-line numbers. Survodutide has also received EMA PRIME (PRIority MEdicines) designation, expediting regulatory review in Europe. These regulatory milestones make Survodutide one of the most clinically de-risked GLP-1/glucagon dual agonist research compounds currently available.

What Research Is Survodutide Most Relevant For?

Survodutide Pharmacokinetics for Research Design

Survodutide Adverse Events: Research Safety Profile

SourceTides Quality Control: Survodutide Peptide

When you buy Survodutide Peptide from SourceTides, every batch undergoes a rigorous multi-stage QC process. Given Survodutide’s structural complexity — 29 amino acids, non-coded Ac4c residue, glycine-serine linker, and C18 diacid moiety — identity confirmation by mass spectrometry is essential and always included alongside HPLC purity data.

Survodutide Regulatory Status by Jurisdiction

Survodutide vs Related GLP-1 / Dual Agonist Research Peptides

Peer-Reviewed References for Survodutide Research

Frequently Researched Alongside Survodutide — Related SourceTides Peptides

Researchers investigating GLP-1R/GCGR dual agonism, metabolic disease, and incretin biology frequently pair Survodutide with the following compounds available from SourceTides:

• Semaglutide research peptide — The gold-standard GLP-1R-selective reference compound; essential for head-to-head comparison studies with Survodutide’s dual mechanism
• Tirzepatide research peptide — GLP-1R/GIPR dual agonist; alternative dual-agonism mechanistic axis to compare with Survodutide’s GLP-1R/GCGR profile
• Retatrutide research peptide — Triple GLP-1R/GIPR/GCGR agonist; studied alongside survodutide for triple-vs-dual receptor comparison in metabolic models
• GLP-1 (7-36) amide research peptide — Native GLP-1 reference for in-vitro receptor assays; essential positive control for survodutide GLP-1R component experiments
• Glucagon research peptide — Native glucagon; GCGR-selective reference for comparison of survodutide’s glucagon receptor activity component
• BPC-157 research peptide — Gastrointestinal protection peptide; studied alongside GLP-1R agonists in gut-biology and mucosal protection research contexts

Frequently Asked Questions: Survodutide Peptide Research